Next big milestone

Dicot intends to enter clinical trials in 2023. Read more about the way forward.

Sexual dysfunctions

Erectile dysfunction affects 52% of all men over the age of 40.

Dicot's panel of experts helps in profiling LIB-1 and preparing it for market acceptance.

Dicot is in preclinical phase with the drug candidate LIB-01, a modern potency drug to better treat erectile dysfunction and premature ejaculation.

In a research collaboration with reputable Pelvipharm, the effect of the substance and future area of use will be clarified.

Toxicology determines the extent of a substance's possible side effects. Read more about Dicot's toxicology program here.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 867137.